Catheter Ablation for Atrial Fibrillation | Lessons Learned From CABANA

19 Marzo 2019

Atrial fibrillation (AF) is the most common heart rhythm disturbance, with an estimated 33.5 million people affected worldwide. By age 75 years, more than 10% of the population will have developed AF. It is well recognized that AF increases the risk of thromboembolic stroke; however, AF also increases the risk of other highly morbid conditions such as heart failure (HF). As a result, even in the modern era of anticoagulation, mortality rates among patients with AF remain up to 2-fold higher than mortality rates among individuals without AF. For many patients, AF also has a major detrimental effect on quality of life, similar to that observed in patients with coronary artery disease requiring percutaneous coronary intervention (PCI) or after a myocardial infarction. Symptoms from AF, which include, but are not limited to, palpitations, dyspnea, and exercise intolerance, are the primary reason that patients seek medical treatment, and physicians treat AF-related symptoms with a therapeutic armamentarium that includes rate control agents, antiarrhythmic drugs, and catheter ablation. Therefore, clinicians hope to achieve 2 potential goals with current therapies directed at AF: to improve quality of life and to decrease AF-related morbidity and mortality…

Prosegui la lettura su “Jama Network